An observational study in Inherited Disease, Rare Diseases and Metabolic Disease, sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Genetic Diseases, Inborn with a site in Italy — 22 open to participants now, 26 under way, 7 of them phase 3. Genetic Diseases, Inborn · Italy.
Among the 65 studies in Genetic Diseases, Inborn with a site in Italy, this one is the 13th largest by planned enrollment of the 19 observational ones that give a count, is one of 8 that started in 2021, is one of 19 observational ones, reaches primary completion later than 18 of the 25 other live ones, and was the 38th registered.
585 studies on the registry are indexed under Genetic Diseases, Inborn; 159 are open to participants now.
Browse Genetic Diseases, Inborn studies →22 of the 65 studies in Genetic Diseases, Inborn with a site in Italy are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Italy, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
BioMarin Pharmaceutical · Sites in Italy, United States, Australia and 6 more countries
Ages 2–17
IRCCS Eugenio Medea · Sites in Italy
Ages 11–39
CSL Behring · Sites in Italy, United States, Belgium and 4 more countries
Ages 18+
Imagine Institute · Sites in Italy, Austria, Belgium and 8 more countries
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 121 Genetic Diseases, Inborn studies recruiting now, 60 (50%) set no upper age limit and 46 (38%) stop at 75 or younger; 86 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 18 · Phase 3 25
First in 1997; this study’s year is marked. 8 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 152 across 240 observational studies indexed under Genetic Diseases, Inborn.
Median enrollment 74 across the 46 interventional studies, 200 across the 19 observational. Of the 37 that completed or were terminated, 21 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 65 have an industry lead sponsor. The 10 most frequent:
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta is the lead sponsor of 84 studies on the registry; 32 are open to participants now.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta has 1 study filed under Genetic Diseases, Inborn — fewer than ten, so there is no comparison to draw.
6 of the studies in Genetic Diseases, Inborn with a site in Italy that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT07884227Istituto Giannina GasliniMulti-Omics Genetic Investigation Strategies to Enhance the Diagnostic Workflow for Rare Diseases | 2026-12-31 |
| NCT07877688Istituto Giannina GasliniExome and Genome Sequencing of DNA Samples, as Required by Specific Research Projects and the Diagnostic Needs of the Gaslini Institute, to Be Performed Within the Framework of the "Joint Genomic Lab" Established Between IGG and IIT | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Genetic Diseases, Inborn with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal collection of clinical, laboratory and instrumental data.
The study provides a collection of retrospective data from adult patients with ultra-rare inherited neurological diseases followed at "Carlo Besta" Neurological Institute from 1st January 2004 until March 2021. Further, prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years. Normal clinical practice will be followed for collection of the prospective data. Follow-up assessment will be performed at least once a year to evaluate the disease course. Based on their clinical manifestations, patients will be assessed by using quantitative functional tests (clinimetric tests such as Timed Up and Go Test) and traditional ordinal scales (such as the scale for the assessment and rating of ataxia (SARA). Moreover, a varying of laboratory and instrumental tests (e.g., neuroimaging, neurophysiological investigations, etc.) will be used according to clinical practice in selected patients.
Adults with ultra-rare inherited degenerative and metabolic neurological diseases
Adults with undiagnosed neurological diseases (when supposed to be inherited)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
collection of retrospective data from adult patients with ultra-rare inherited neurological diseases
Other: collection of data
prospective data will be collected starting from March 2021 (date of protocol approval) and spanning the next ten years
Other: collection of data
collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
Verbal (letter) fluency
Repeated Montreal Cognitive Assessment (MoCA) letter F fluency subtest
Time frame: 10 years
Stance and gait performances [Time Frame: 10 years] Stance and gait performances
Repeated SARA (Scale for the Assessment and Rating Ataxia) stance subtask, ambulation index (AI) and Timed Up and Go (TUG) test
Time frame: 10 years
Upper limb motor function
Repeated ONLS (Overall Neuropathy Limitation Scale) arm scale
Time frame: 10 years
Swallowing function (dysphagia)
Repeated NP-C mDRS (Niemann-Pick type C modified disability rating scale) swallowing scale
Time frame: 10 years
Speech function (dysarthria)
Repeated NP-C mDRS language scale
Time frame: 10 years
Bladder function
Repeated AADS (Adult Adrenoleukodystrophy Disability Score) Bladder function scale
Time frame: 10 years
Sleep
Repeated assessment of presence or absence of sleep disturbances
Time frame: 10 years
Quality of life
Repeated EuroQol-5D-5L (EQ-5D-5L) questionnaire
Time frame: 10 years
Plan to share: Undecided
Started Mar 2021 (actual). Primary completion is estimated for Mar 2031, 120 months after the start.
Of 94 non-industry observational studies under Genetic Diseases, Inborn, half reached primary completion within 124 months of starting (the median), counting those still running; a quarter within 46. This study's planned 120 months is close to that.
Counting every sponsor, half of 128 studies reached it within 110 months; a quarter within 46 and three quarters within 193.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta